104 related articles for article (PubMed ID: 18856023)
1. [Severe oesophagus injury as a complication during treatment with risedronic acid].
Bijlsma A; Blokzijl H; Vecht J
Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2105-7. PubMed ID: 18856023
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates. A cornerstone of osteoporosis treatment.
Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
[No Abstract] [Full Text] [Related]
3. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
Ringe JD; van der Geest SA; Möller G
Drugs Aging; 2006; 23(7):569-78. PubMed ID: 16930085
[TBL] [Abstract][Full Text] [Related]
4. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
5. Risedronate-induced Hepatitis.
Phillips MB
Am J Med; 2007 Mar; 120(3):e1-2. PubMed ID: 17349419
[No Abstract] [Full Text] [Related]
6. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850
[TBL] [Abstract][Full Text] [Related]
7. Monthly risedronate (Actonel) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843
[No Abstract] [Full Text] [Related]
8. Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Gennari L; Bilezikian JP
Lancet; 2009 Apr; 373(9671):1225-6. PubMed ID: 19362657
[No Abstract] [Full Text] [Related]
9. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
Dougherty JA
Ann Pharmacother; 2002 Mar; 36(3):512-6. PubMed ID: 11895066
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Kishimoto H
Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
[TBL] [Abstract][Full Text] [Related]
11. Risedronic acid. NE 58095, risedronate sodium, Actonel.
Drugs R D; 1999 Mar; 1(3):218-20. PubMed ID: 10566029
[No Abstract] [Full Text] [Related]
12. How to prevent glucocorticoid-induced osteoporosis.
Bachmeyer C; Gauthier M
Cleve Clin J Med; 2010 Nov; 77(11):762; author reply 762. PubMed ID: 21086710
[No Abstract] [Full Text] [Related]
13. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Sato S
Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
16. [Acute exacerbation of a chronic esophagitis].
Winkler-Budenhofer UC; Ihrler S; Göke B; Kolligs FT
Dtsch Med Wochenschr; 2009 Jul; 134(30):1517-9. PubMed ID: 19603366
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic hypocalcemia due to oral risedronate therapy.
Dogru T; Sonmez A; Tasci I; Genc H
Indian J Med Sci; 2005 Dec; 59(12):542-3. PubMed ID: 16385174
[No Abstract] [Full Text] [Related]
18. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
[TBL] [Abstract][Full Text] [Related]
19. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
20. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
